Paul A. Mahon Sells 6,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR – Get Rating) EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction on Thursday, January 19th. The shares were sold at an average price of $258.95, for a total transaction of $1,553,700.00. Following the sale, the executive vice president now directly owns 36,397 shares of the company’s stock, valued at approximately $9,425,003.15. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

United Therapeutics Stock Up 0.6 %

United Therapeutics stock opened at $261.70 on Friday. The firm has a market cap of $11.93 billion, a price-to-earnings ratio of 17.80, a P/E/G ratio of 1.54 and a beta of 0.62. The company has a debt-to-equity ratio of 0.18, a current ratio of 9.68 and a quick ratio of 9.39. United Therapeutics Co. has a fifty-two week low of $158.38 and a fifty-two week high of $283.09. The firm has a fifty day moving average price of $270.84 and a two-hundred day moving average price of $241.22.

United Therapeutics (NASDAQ:UTHR – Get Rating) last released its earnings results on Wednesday, November 2nd. The biotechnology company reported $4.91 earnings per share for the quarter, topping analysts’ consensus estimates of $3.57 by $1.34. United Therapeutics had a net margin of 38.03% and a return on equity of 16.63%. The firm had revenue of $516.00 million during the quarter, compared to analyst estimates of $492.92 million. As a group, analysts forecast that United Therapeutics Co. will post 16.63 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in shares of United Therapeutics by 3.8% during the 3rd quarter. Vanguard Group Inc. now owns 4,411,616 shares of the biotechnology company’s stock worth $923,703,000 after purchasing an additional 163,542 shares during the period. BlackRock Inc. increased its holdings in shares of United Therapeutics by 0.3% during the 3rd quarter. BlackRock Inc. now owns 4,327,368 shares of the biotechnology company’s stock worth $906,061,000 after purchasing an additional 13,196 shares during the period. Renaissance Technologies LLC increased its holdings in shares of United Therapeutics by 1.0% during the 2nd quarter. Renaissance Technologies LLC now owns 2,793,591 shares of the biotechnology company’s stock worth $658,282,000 after purchasing an additional 28,378 shares during the period. Wellington Management Group LLP increased its holdings in shares of United Therapeutics by 73.7% during the 1st quarter. Wellington Management Group LLP now owns 1,675,414 shares of the biotechnology company’s stock worth $300,585,000 after purchasing an additional 710,668 shares during the period. Finally, State Street Corp increased its holdings in shares of United Therapeutics by 7.2% during the 1st quarter. State Street Corp now owns 1,626,491 shares of the biotechnology company’s stock worth $291,809,000 after purchasing an additional 109,226 shares during the period. Institutional investors own 95.63% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on UTHR. Argus lifted their price objective on shares of United Therapeutics from $250.00 to $300.00 and gave the company a “buy” rating in a research note on Wednesday, January 11th. JPMorgan Chase & Co. lifted their price objective on shares of United Therapeutics from $240.00 to $265.00 and gave the company an “overweight” rating in a research note on Thursday, November 3rd. UBS Group began coverage on shares of United Therapeutics in a research note on Tuesday, December 6th. They issued a “buy” rating and a $320.00 price objective for the company. Oppenheimer lifted their price objective on shares of United Therapeutics from $325.00 to $375.00 and gave the company an “outperform” rating in a research note on Thursday, November 3rd. Finally, The Goldman Sachs Group began coverage on shares of United Therapeutics in a research note on Monday, December 5th. They issued a “sell” rating and a $230.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $283.64.

United Therapeutics Company Profile

(Get Rating)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.